Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies

BACKGROUND: In the PATHWAY-2 study of resistant hypertension, spironolactone reduced blood pressure substantially more than conventional antihypertensive drugs. We did three substudies to assess the mechanisms underlying this superiority and the pathogenesis of resistant hypertension. METHODS: PATHW...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Lancet Diabetes Endocrinol
Autores principales: Williams, Bryan, MacDonald, Thomas M, Morant, Steve V, Webb, David J, Sever, Peter, McInnes, Gordon T, Ford, Ian, Cruickshank, J Kennedy, Caulfield, Mark J, Padmanabhan, Sandosh, Mackenzie, Isla S, Salsbury, Jackie, Brown, Morris J
Formato: Artigo
Lenguaje:Inglês
Publicado: The Lancet, Diabetes & Endocrinology 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5966620/
https://ncbi.nlm.nih.gov/pubmed/29655877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2213-8587(18)30071-8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares